Cramer Gives His Opinion On Applied Materials, Coinbase And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Applied Materials, Inc. (NASDAQ: AMAT) reported an excellent quarter.
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors.
The Company was founded in 1996 and went public in June last year.
Morgan Stanley Maintains Equal-Weight on Royalty Pharma, Lowers Price Target to $46
Morgan Stanley analyst Matthew Harrison maintains Royalty Pharma (NASDAQ:RPRX) with a Equal-Weight and lowers the price target from $51 to $46.
The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 10)
Recap: Royalty Pharma Q2 Earnings
Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 26.26% year over year to $0.73, which beat the estimate of $0.69.
Royalty Pharma Q2 Sales $555.00M Beat $483.42M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $555.00 million which beat the analyst consensus estimate of $483.42 million by 14.81 percent. This is a 8.61 percent increase over sales of $511.00 million the
Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell
• Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Tigress Financial Initiates Coverage On Royalty Pharma with Buy Rating, Announces Price Target of $50
Tigress Financial analyst Ivan Feinseth initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy rating and announces Price Target of $50.
Royalty Pharma Insights: Return On Capital Employed
Royalty Pharma (NASDAQ:RPRX) showed a loss in earnings since Q4, totaling $229.30 million. Sales, on the other hand, increased by 0.18% to $573.03 million during Q1. Royalty Pharma reached earnings of $314.06 million and sales of $572.00 million in Q4.